Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier
WebMD

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine
WebMD

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion
    WebMD

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community
    WebMD

    Community

    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Epilepsy Health Center

Font Size
A
A
A

New Epilepsy Drug Potiga Gets FDA Panel Nod

Advisory Panel: Potiga Works and Risks Can Be Minimized; Full FDA Approval Likely
By
WebMD Health News
Reviewed by Laura J. Martin, MD

Aug. 11, 2010 -- Potiga, a new epilepsy drug, should be approved in the U.S. as an add-on treatment, an FDA expert advisory panel today voted.

Potiga, known generically as ezogabine in the U.S. and as retigabine elsewhere, works differently than current epilepsy drugs. That's a good thing, as about a third of epilepsy patients do not get satisfactory seizure control from treatment

But Potiga can have dangerous side effects. Most worrying to the panel were the drug's effects on the bladder -- particularly urinary retention, sometimes resulting in urinary infections. But in the end, the panel agreed that this risk could be minimized by a patient-monitoring program.

Some panel members wanted the FDA to require a more stringent monitoring program than the one proposed by Valeant Pharmaceuticals International, which is developing the drug with GlaxoSmithKline. Other panel members wanted the FDA to ensure that doctors who prescribe Potiga would be vigilant for side effects and would use the drug only in patients for whom it is approved.

Panelists also expressed concern that doctors be alert for other side effects besides bladder problems in patients taking the drug. Based on clinical trials, those most commonly seen include drowsiness, dizziness, fatigue, and confusion.

Potiga is intended for the treatment of partial seizures, the most common type of seizure in adults. A partial seizure affects only part of the brain but may result in a wide range of symptoms.

The drug works by opening potassium signaling channels in the brain. This has the effect of stabilizing the electrical current in the brain and prevents the sudden bursts of activity that occur with seizures.

In an evaluation of Potiga clinical trials provided to the panel, the FDA said the drug helped cut the number of seizures patients experienced. Because it wears off quickly, the drug must be taken three times a day.

Today on WebMD

human head and brain waves
Causes, symptoms, and treatments.
Grand mal seizure
How is each one different?
 
marijuana plant
CBD, a plant chemical, may cut down seizures.
prescription bottle
Which medication is right for you?
 
Seizures Driving
Article
Questions for Doctor Epilepsy
Article
 
Graces Magic Diet
Article
Pills spilling from bottle in front of clock
Article
 
first aid kit
Article
Caring Child Epilepsy
Article
 
Making Home Safe
Article
epilepsy monitoring
Article